Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD10046 vs NovoMix 30 in Type 2 Diabetes (Phase 3, China)
CTR20171474Phase 3Completed
- Sponsor
- YiChang HEC ChangJiang Pharmaceutical
- Start
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of biphasic insulin aspart in type 2 diabetes mellitus (T2DM), sponsored by YiChang HEC ChangJiang Pharmaceutical. Started Jan 2018; status: completed.
02
Drugs
biphasic insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20171474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171474.